Exploring the therapeutic efficacy of glioma vaccines based on allo- and syngeneic antigens and distinct immunological costimulation activators

A. Stathopoulos, C. Pretto, L. Devillers, D. Pierre, F.M. Hofman, A.L. Epstein, H. Farghadani, C.A. Kruse, M.R. Jadus, T.C. Chen, V.E.J.C. Schijns

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The efficacy of a various immunotherapeutic immunisation strategies for malignant glioma brain cancer was evaluated in the syngeneic CNS-1 Lewis rat glioma model. A prototype glioma cancer vaccine, which was composed of multivalent antigens derived from allogeneic and syngeneic cells and lysates, formed the prototype preparation of antigens. These antigens reflect the autologous antigens derived from the patient’s surgically removed tumor tissue, as well as allogeneic antigens form glioma tumor tissue surgically removed from donor patients. This antigen mixture provides a broad spectrum of tumor associated antigens (TAA) and helps to prevent escape of tumor immune surveillance when given as a vaccine. This antigen preparation was administered in a therapeutic setting with distinct single or multiple co-stimulation-favouring immunostimulants and evaluated for inhibition of tumor growth. Our prototype vaccine was able to arrest progression of tumor growth when co-delivered in a specific regimen togetherwith the costimulating multi-TLR agonist, Bacille Calmette Guerin (BCG) and interleukin-2, or with the Toll-Like receptor (TLR) 7/8 activator resiquimod
Original languageEnglish
Article numberS5:004
JournalJournal of Clinical and Cellular Immunology
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint Dive into the research topics of 'Exploring the therapeutic efficacy of glioma vaccines based on allo- and syngeneic antigens and distinct immunological costimulation activators'. Together they form a unique fingerprint.

Cite this